Search
Precision BioSciences Inc
DTILAdd to Watchlist
8.180USD
+0.300+3.81%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
211.09MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+3.81%
5 Days
+12.21%
1 Month
+27.61%
6 Months
+99.51%
Year to Date
+96.63%
1 Year
+88.48%
Key Figures
7.960Open
8.240High
600.93KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
2.33%Turnover Ratio
7.880Prev. Close
7.845Low
2.57MTurnover
29.45P/E Static
2.77P/B
0.00%Div Yield TTM
-33.16%ROA
8.82052wk High
0.90Volume Ratio
7.17MNet Profit
25.81MShares
-2.1003EPS TTM
1.31Beta
-70.93%ROE
3.53052wk Low
5.01%Amplitude
100.00%Gross Margin
211.09MMarket Cap
5.41Reward/Risk
4.24%Risk Rate
TradingKey Stock Score of Precision BioSciences Inc
Currency: USD Updated: 2026-07-02Key Insights
Precision BioSciences Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 48 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Strong Buy, with the highest price target at 29.60.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Precision BioSciences Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Precision BioSciences Inc Highlights
StrengthsRisks
Precision BioSciences, Inc. is a clinical-stage gene editing company dedicated to improving life (DTIL) with its proprietary ARCUS genome editing platform. Using ARCUS, the Company’s pipeline is comprised of in vivo gene editing candidates designed to deliver cures for a range of genetic and infectious diseases. The ARCUS platform is used to develop in vivo gene editing therapies for gene edits, including gene insertion, elimination, and excision. The Company's in vivo gene editing pipeline programs include PBGENE-HBV, PBGENE-3243, PBGENE-DMD, PBGENE-LIVER, PBGENE-CNS, PBGENE-NVS and iECURE-OTC. PBGENE-HBV is its lead in vivo gene editing program designed to eliminate cccDNA, the key source of replicating hepatitis B virus (HBV) and inactivating integrated HBV DNA in hepatocytes. Its PBGENE-3243 program is a first of its kind potential treatment for m.3243 associated mitochondrial disease. The Company's iECURE-OTC program is developed in partnership with iECURE, Inc.
Growing
The company is in a growing phase, with the latest annual income totaling USD 34.26M.
Turnaround to Loss
The company's performance has turned to a loss, with the latest annual loss of USD .
Undervalued
The company’s latest PE is -3.89, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 15.71M shares, increasing 16.10% quarter-over-quarter.
Held by Steven Cohen
Star Investor Steven Cohen holds 25.79K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.80.
Analyst Rating
Based on
5
analysts
Strong Buy
Current Rating
29.600
Target Price
+275.63%
Upside Space
Precision BioSciences Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Precision BioSciences Inc Info
Precision BioSciences, Inc. is a clinical-stage gene editing company dedicated to improving life (DTIL) with its proprietary ARCUS genome editing platform. Using ARCUS, the Company’s pipeline is comprised of in vivo gene editing candidates designed to deliver cures for a range of genetic and infectious diseases. The ARCUS platform is used to develop in vivo gene editing therapies for gene edits, including gene insertion, elimination, and excision. The Company's in vivo gene editing pipeline programs include PBGENE-HBV, PBGENE-3243, PBGENE-DMD, PBGENE-LIVER, PBGENE-CNS, PBGENE-NVS and iECURE-OTC. PBGENE-HBV is its lead in vivo gene editing program designed to eliminate cccDNA, the key source of replicating hepatitis B virus (HBV) and inactivating integrated HBV DNA in hepatocytes. Its PBGENE-3243 program is a first of its kind potential treatment for m.3243 associated mitochondrial disease. The Company's iECURE-OTC program is developed in partnership with iECURE, Inc.
Ticker SymbolDTIL
CompanyPrecision BioSciences Inc
CEOAmoroso (Michael)
Websitehttps://precisionbiosciences.com/
Related Instruments
+1.62%
+3.50%
+6.14%
+3.96%
+3.31%
+3.72%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+4.11%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
52852.900
+10.400 (+0.02%)
29669.900
+358.500 (+1.22%)
7507.800
+36.300 (+0.49%)
14963.000
+160.000 (+1.08%)
69676.000
+1528.000 (+2.24%)
6412.400
+59.600 (+0.94%)
68.683
+0.339 (+0.50%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4174.610
+52.700 (+1.28%)
FAQs
What is the current price of Precision BioSciences Inc (DTIL)?
The current price of Precision BioSciences Inc (DTIL) is 8.18.
What is the symbol of Precision BioSciences Inc?
The ticker symbol of Precision BioSciences Inc is DTIL.
What is the 52-week high of Precision BioSciences Inc?
The 52-week high of Precision BioSciences Inc is 8.82.
What is the 52-week low of Precision BioSciences Inc?
The 52-week low of Precision BioSciences Inc is 3.53.
What is the market capitalization of Precision BioSciences Inc?
The market capitalization of Precision BioSciences Inc is 211.09M.
Is Precision BioSciences Inc (DTIL) currently rated as Buy, Hold, or Sell?
According to analysts, Precision BioSciences Inc (DTIL) has an overall rating of STRONG BUY, with a price target of 29.60.
What is the Earnings Per Share (EPS TTM) of Precision BioSciences Inc (DTIL)?
The Earnings Per Share (EPS TTM) of Precision BioSciences Inc (DTIL) is -3.56.